2.43

3.57% -0.09

Minerva Neurosciences Inc (NERV)

Overview News Price History Discussions Forecast Stock Split

Minerva Neurosciences Inc stock is currently priced at $2.43, with a 24-hour trading volume of 5,770. It has seen a -3.57% decreased in the last 24 hours and a -8.65% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $2.51 pivot point. If it approaches the $2.42 support level, significant changes may occur.

Previous Close:

$2.52

Open:

$2.5

24h Volume:

5,770

Market Cap:

$16.99M

Revenue:

Net Income/Loss:

$-30.01M

P/E Ratio:

-0.488

EPS:

-4.98

Net Cash Flow:

$-14.78M

1W Performance:

-2.80%

1M Performance:

-8.65%

6M Performance:

-46.36%

1Y Performance:

+4.29%

1D Range:

$2.43

$2.505

52W Range:

$2.2864

$13.49

Minerva Neurosciences Inc Stock (NERV) Company Profile

Name

Minerva Neurosciences Inc

Sector

Healthcare (1197)

Industry

Biotechnology (688)

Phone

617 600 7373

Address

1601 Trapelo Road, Suite 286, Waltham, MA

Employee

Twitter

Next Earnings Date

2024-05-13

Latest SEC Filings

NERV's Discussions on Twitter

Minerva Neurosciences Inc Stock (NERV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-08-20	Reiterated	H.C. Wainwright	Buy
May-14-20	Initiated	BTIG Research	Buy
Oct-02-19	Reiterated	Chardan Capital Markets	Buy
Sep-25-19	Initiated	Chardan Capital Markets	Buy
Sep-18-19	Initiated	William Blair	Outperform
May-31-19	Initiated	H.C. Wainwright	Buy
Sep-01-17	Initiated	Citigroup	Buy
Mar-06-17	Resumed	Jefferies	Buy
May-12-16	Resumed	Jefferies	Buy

View All

Minerva Neurosciences Inc Stock (NERV) Latest News

Dow Dips Over 100 Points; J.M. Smucker Posts Upbeat Earnings

Benzinga

Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Benzinga

Crude Oil Gains 1%; Macy's Plans To Close 150 Stores

Benzinga

Nasdaq Rises 50 Points; Lowe's Earnings Top Views

Benzinga

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates

GlobeNewswire Inc.

Minerva Neurosciences Inc Stock (NERV) Financials Data

Minerva Neurosciences Inc (NERV) Net Income 2024

NERV net income (TTM) was -$30.01 million for the quarter ending December 31, 2023, a +6.55% increase year-over-year.

Minerva Neurosciences Inc (NERV) Cash Flow 2024

NERV recorded a free cash flow (TTM) of -$14.78 million for the quarter ending December 31, 2023, a +40.01% increase year-over-year.

Minerva Neurosciences Inc (NERV) Earnings per Share 2024

NERV earnings per share (TTM) was -$4.66 for the quarter ending December 31, 2023, a +22.46% growth year-over-year.

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.